Medlab Clinical (MDC.AX) Stock Price
Medlab Clinical Price
Revenue at Medlab Clinical has contracted by 30.9% per year over the past 10 years to 14,600.00 AUD. Medlab Clinical's net margin stands at -14,593.2%, down from -458.2% several years earlier.
Medlab Clinical stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Medlab Clinical business model & stock analysis
Frequently asked questions about Medlab Clinical
The business model of Medlab Clinical Ltd is focused on innovative medical research and the development of therapeutic formulations. As a leading Australian biotech company, Medlab Clinical specializes in developing and commercializing nutraceuticals, pharmaceuticals, and diagnostic tools to improve patient outcomes. Medlab Clinical aims to leverage its expertise in advanced delivery platforms and nutraceutical products to address various health conditions, including pain management, depression, and chronic diseases. By prioritizing research-backed solutions and strategic collaborations, Medlab Clinical aims to transform healthcare through evidence-based treatments and personalized medicine.
Medlab Clinical Ltd is primarily active in the healthcare and biotechnology industries.
The main competitors of Medlab Clinical Ltd in the market include companies such as Sonic Healthcare Limited, Healius Limited, Integral Diagnostics Limited, and Capitol Health Limited. These companies also operate in the medical diagnostics and healthcare industry, offering similar services and solutions. Despite facing competition, Medlab Clinical Ltd has established a strong presence and reputation through its innovative offerings, research collaborations, and dedication to improving patient outcomes.
Medlab Clinical Ltd is an Australian biotechnology company specializing in developing and commercializing novel therapeutic products for chronic diseases. Established in 2012, Medlab Clinical has rapidly emerged as a leader in the medical research and development sector. With a strong focus on scientific innovation, the company aims to improve patient outcomes through its advanced drug delivery systems and targeted treatments. Medlab Clinical has garnered recognition for its cutting-edge medical advancements, including patented NanoCelle™ technology. With a commitment to research excellence and a dedicated team of experts, Medlab Clinical continues to revolutionize the field of biotechnology and pave the way for groundbreaking medical solutions.
Some significant milestones achieved by Medlab Clinical Ltd include the successful completion of a Phase 2 trial for their lead drug candidate, NRGBiotic, for managing depression symptoms. The company has also received various regulatory approvals and successfully launched several products, including Nanabis, a cannabis-based product for pain management. Medlab Clinical Ltd has established collaborations with prestigious research institutions and universities worldwide, contributing to advancements in medical research. The company continues to expand its global reach, with strategic partnerships and acquisitions, positioning itself as an innovative leader in the field of personalized medicine and nutraceuticals.
Medlab Clinical Ltd is primarily present in Australia and New Zealand.
Medlab Clinical Ltd is a renowned company that upholds its core values and corporate philosophy with utmost dedication. The company firmly believes in promoting innovative and evidence-based medical research to improve patient outcomes. With a focus on scientifically driven products, Medlab Clinical Ltd strives to develop and deliver advanced therapeutic solutions in the field of medical science. The company values integrity, commitment, and excellence, as it strives to provide cutting-edge diagnostics and personalized medicine. Medlab Clinical Ltd's dedication to upholding these values has made it a trusted name in the healthcare industry, offering high-quality solutions for better patient care.
5 analysts currently rate the Medlab Clinical stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Medlab Clinical to generate revenue of 17.90 M AUD and earnings per share of -3.52 AUD.
Converted at the current exchange rate, the Medlab Clinical share trades at 4.09 EUR (6.60 AUD).
The Medlab Clinical share (MDC.AX) is listed on 1 stock exchanges, including: ASX (MDC.AX).
Medlab Clinical Ltd is an Australian company specializing in the development and provision of clinical diagnostic solutions for medical professionals. The company operates in three main divisions: diagnostic services, biotechnology, and research and development. The diagnostic services provide a variety of laboratory tests for medical conditions, including hormone tests, immune tests, and microbiology tests. The biotechnology division focuses on developing groundbreaking drugs and therapies for serious diseases such as inflammation and cancer. The research and development division invests in innovative technologies and products to meet the needs of medical professionals and their patients. Medlab Clinical offers a wide range of products and services, including probiotics for digestive and gut health, skin-friendly nutraceuticals, and blood tests for various medical conditions. The company's strong business model is based on innovation, research, and customer service. It aims to maintain its reputation as a leading provider of clinical diagnostic solutions and biotechnological developments through continuous innovation and excellent customer satisfaction.
The expected revenue of Medlab Clinical is 17.90 M AUD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Medlab Clinical is -8.05 M AUD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Medlab Clinical is currently -1.87. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medlab Clinical stock.
The price-to-sales ratio (P/S) of Medlab Clinical is currently 0.84. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medlab Clinical stock.
The Eulerpool Quality Score for Medlab Clinical is 2/10.
The ISIN of Medlab Clinical is AU000000MDC8. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Medlab Clinical is A14R7W. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Medlab Clinical is MDC.AX. The ticker symbol is used to trade Medlab Clinical shares on the stock exchange.
Medlab Clinical stock
Medlab Clinical Peer Group
Medlab Clinical Ticker
Medlab Clinical FIGI
All fundamentals and in-depth analysis of Medlab Clinical
Our stock analysis for Medlab Clinical stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medlab Clinical. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.